Cosmo Bio Company,Limited Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	369	653	790	1,099
Depreciation & Amortization	136	148	141	166
Loss (Gain) From Sale of Assets	1	-	-	-
Loss (Gain) From Sale of Investments	-5	-	-	-
Other Operating Activities	-194	-186	-280	-384
Change in Accounts Receivable	-140	-40	-73	75
Change in Inventory	-25	97	-267	-245
Change in Accounts Payable	73	50	-22	-12
Change in Other Net Operating Assets	26	14	-5	-51
Operating Cash Flow	241	736	284	648
Operating Cash Flow Growth	-67.25%	159.16%	-56.17%	-19.30%
Capital Expenditures	-216	-67	-55	-31
Sale (Purchase) of Intangibles	-60	-33	-49	-110
Investment in Securities	103	-700	-202	-
Other Investing Activities	-44	42	15	-4
Investing Cash Flow	-217	-758	-291	-145
Repurchase of Common Stock	-299	-	-	-194
Common Dividends Paid	-175	-197	-232	-223
Other Financing Activities	-5	-4	-4	-3
Financing Cash Flow	-479	-201	-236	-420
Foreign Exchange Rate Adjustments	22	13	24	12
Miscellaneous Cash Flow Adjustments	-	-	1	-
Net Cash Flow	-433	-210	-218	95
Free Cash Flow	25	669	229	617
Free Cash Flow Growth	-96.26%	192.14%	-62.89%	-19.56%
Free Cash Flow Margin	0.25%	7.16%	2.40%	6.68%
Free Cash Flow Per Share	4.30	114.78	39.45	106.22
Cash Income Tax Paid	193	185	279	385
Levered Free Cash Flow	-356.63	481.63	147.63	290.25
Unlevered Free Cash Flow	-356.63	481.63	147.63	290.25
Change in Working Capital	-66	121	-367	-233

Source: S&P Global Market Intelligence. Standard template. Financial Sources.